If successful, these novel agents could be used to screen/select of chemotherapy-resistant patients with recurrent GBM or PCNSL for targeted anti-CXCR4 chemotherapy (singly or in combination with other treatments) in the future. Here, CXCR4 is linked to glioblastoma.